Abstract: Described herein are compositions for promoting hair growth and/or treating or preventing hair loss in a mammalian subject. In certain embodiments, the mammalian subject is a human male or a human female. Methods of making and using the same are also described. The compositions in various embodiments may comprise: a tea extract which may comprise a polyphenol, e.g., epigallocatechin gallate; an extract from Larix europaea which may comprise the flavonoid taxifolin; a natural ingredient that antagonizes or mitigates the proliferation of Gram-positive bacteria in the hair shaft passageway; compounds including zinc chloride and/or hexamidine diisethionate; follicle stimulator. e.g., caffeine, an ingredient that improves the health of the dermis. e.g., sodium hyaluronate; and/or ingredients specifically tailored for male or female subjects, e.g., Serenoa serrulata fruit extract or extract of Pterocarpus marsupium.

Abstract: The present invention relates to a cosmetic active substance comprising galactomannans obtained from Medicago sativa seeds and its cosmetic uses. This active substance has a complexion-perfecting effect, and is mixed and multi-ethnic, designed for all types of healthy skin: Caucasian, Asian, African-American and Hispanic-American, whatever their age.

Abstract: A composition for a krill-powder-based skin care product and a method of use thereof rejuvenates the skin and helps maintain a healthy skin and a healthy integumentary system. The composition includes a quantity of krill powder, a quantity of hyaluronic-acid powder, a quantity of calcium-benzoate clay powder, a quantity of aloe-vera powder, a quantity of vitamin-A palmitate powder, and a quantity of colloidal silver. The quantity of krill powder, the quantity of hyaluronic-acid powder, the quantity of calcium-benzoate clay powder, the quantity of aloe-vera powder, the quantity of vitamin-A palmitate powder, and the quantity of colloidal silver are homogeneously mixed into a final powder compound that is non-hydrated. The final powder compound can be rehydrated at the time of application to increase the shelf life of the composition. Further, the composition can be infused together with potential additional ingredients such as retinoid, gelatin, and liquid solvents.

Abstract: The present invention provides a composition for improving skin compatibility, comprising: honey, in which a contact angle of water on the skin to which the composition has been applied is 30 degrees or less. The present invention also provides a method for improving skin compatibility, comprising applying the composition to the skin.

Abstract: A topical composition includes minoxidil, a cosolvent, an ?-hydroxy acid and water. The cosolvent includes alcohol. A weight ratio of the alcohol to the water is 1:1.4 to 1:10. A method for manufacturing the topical composition includes the following steps: dissolving the ?-hydroxy acid in the water; adding the cosolvent to obtain a mixed solution; and adding the minoxidil to the mixed solution. A use of the topical composition is for treating hair loss or promoting hair growth.

Abstract: The present invention relates to a stable injectable composition of Triamcinolone acetonide and a method of preparing same, which is stable at controlled room temperature between 200 C-250 C and packaged in glass material. Specifically, the triamcinolone acetonide injection of the present invention shows improved viscosity within range of 10-30 cps and osmolality within range of 270 to 370 mOsm/kg.

Abstract: The present invention provides a method of treating an infectious disease. The method comprises the step of administering to a subject in need thereof an effective amount of (i) a polymer-flavonoid conjugate, (ii) a flavonoid oligomer, or (iii) micelles having a shell formed by one or more polymer-flavonoid conjugates or one or more flavonoid oligomers, or the combination thereof, and having an agent encapsulated within the shell. The present method is effective to treat viral infection, e.g., severe acute respiratory syndrome coronavirus (SARS-CoV), enterovirus virus, HIV, hepatitis B virus, MERS-CoV, influenza virus, Dengue virus, respiratory syncytial virus, hepatitis C virus, monkeypox virus, human papillomavirus, methicillin-resistant Staphylococcus aureus, Pseudomonas, tuberculosis, Bacillus anthracis, Tetani bacterium, Streptococcus pneumoniae, meningococcus, Escherichia coli, Legionella, Neisseria gonorrhea, Neisseria meningitidis, and Salmonella.

Abstract: Ionizable lipids with a disulfide moiety and lipid nanoparticles comprising said lipids are disclosed. In select preferred embodiments, the ionizable lipids have a structure of formulae 11-15. The lipid nanoparticles formed from the ionizable lipids can be used as delivery vehicles for medicinal small molecules, antibodies, nucleotides, and polypeptides. Such nanoparticles can be used as vaccines or the treatment of cancer.

Abstract: The disclosure is directed to olanzapine, compositions and methods of use thereof, wherein the olanzapine exhibits good flowability and syringeability.

Abstract: The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.

Abstract: A polymer substantially consisting of a succession of monomers according to the formula I for use in increasing the bioavailability of pharmaceutical component to a mammalian patient, a process for formulating the polymer and the pharmaceutical component.

Abstract: The present invention generally relates to the field of biopolymers. In one aspect. the invention is directed to a method of preparing lyophilized and reconstituted gellan gum compositions. In further aspects. the invention relates to lyophilized compositions comprising gellan gum, reconstituted gellan gum compositions. dosage-unit formulations comprising lyophilized gellan gum, and their use in medicine or other sterile applications.

Abstract: Provided is a method of synthesizing polymer particles, including: introducing vapor-phase reagents into a reactor having a substrate; forming condensed droplets of the reagents on the substrate; initiating polymerization; and polymerizing the condensed droplets of the reagents, thereby forming polymer particles. Polymer particles are also provided, including those incorporating therapeutic agents.

Abstract: Provided are high concentration stable formulations of anti-CSF1R/CSF1 antibodies. An example formulation includes 105 to 250 mg/mL of the antibody, 100 mM to 200 mM of arginine glutamate or arginine HCl, 10 mM to 50 mM histidine, and 0.015 to 0.035 w/v % of polysorbate 80, at a pH of 5.4 to 5.6. Also provided are methods of using the formulations for treating diseases.

Abstract: This disclosure relates to a dual release drug delivery system for use in enhancing female sexual desire in the treatment of Female Sexual Interest and Arousal Disorder (FSIAD). the composition comprises a core comprising cellulose, a filler selected from an organic and/or an inorganic salt, and a first active ingredient comprising a PDE 5 inhibitor for delayed immediate release. a first coating surrounding the core, comprising a hydrophobic polymer and a hydrophilic substance; and a second coating surrounding the first coating, comprising a second active ingredient which is a testosterone, or a functional analogue or derivative of testosterone, for immediate release. The delayed release of the first active ingredient is an immediate release occurring between 2 to 6 hours after the release of the second active ingredient; and the second active ingredient is present in an amount equivalent to from 0.3 to 1.5 mg of testosterone, or in an amount equivalent to no less than 1.0 mg of testosterone.

Abstract: The disclosure provides a solid oral dosage form comprising bictegravir or a pharmaceutically acceptable salt thereof, and lenacapavir or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: The present invention relates to water-insoluble micro-dispersions of calcium alginate, and in particular for water-insoluble micro-dispersions for the preparation of capsules and capsule films as enteric coatings for oral administration of medications, nutritional components and supplements.

Abstract: The present disclosure relates to coating formulations for use in multi-ingredient dosage forms comprising vitamin C and/or choline. The coating formulations surround the vitamin C and/or the choline in a multi-ingredient dosage form, which prevents spotting of the dosage forms.

Abstract: A capsule consisting of a polymeric shell surrounding a core, the core comprises an organic compound, the polymeric shell comprises a poly(amino acid) and is obtainable by interfacial polymerization of a N-carboxy-anhydride monomer according to general structure (I). The organic compound is a marine oil, a vegetable oil, an essential oil, a fragrance, a flavour, an insect repellent, a flame retardant, an active pharmaceutical ingredient or an agrochemical.

Abstract: The current invention relates to ionizable lipid-like compound according to Formula (I) or pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The present invention also provides a lipid nanoparticle comprising an ionizable lipid-like compound according to Formula I and one or more RNA molecules, as well as a pharmaceutical composition or vaccine, comprising such lipid nanoparticles.

Abstract: A method of treatment or prevention of HIV and other viral infection comprising the administration of a biopolymer-based hydrogel nanoparticles and/or microparticles. In preferred embodiments, the particles comprise chitosan, hydroxyethyl cellulose (HEC), and linseed oil polyol. These biopolymer-based hydrogel nanoparticles and/or microparticles are antiviral agents that can be employed alone or in combination with other drugs for treatment of the viral infection. Further, the pre-treatment with the particles is highly effective at inhibiting viruses. Therefore, this antiviral biopolymer-based hydrogel nanoparticles and/or microparticles may also be employed as a prophylactic.

Abstract: The invention relates to the field of pharmaceutical compositions comprising proteins as therapeutic active ingredient. More particularly it is directed to di-block or multi-block copolymers used as excipients, and in particular as stabilizer, in protein-containing dried compositions, filaments obtained from these dried compositions, implantable drug delivery device formed from these filaments and to methods of producing such compositions, filaments and devices.

Abstract: The present application includes a composition comprising a non-racemic mixture R-1,3-butanediol and S-1,3-butane-diol, wherein the R-1,3-butanediol is present in the composition in a greater amount by enantiomeric equivalents, relative to S-1,3-butanediol, and uses thereof.

Abstract: Described herein, inter alia, are compositions, formulations, methods, and systems for reducing regional fat deposits and treating fat-related conditions.

Abstract: An orally ingestible contraceptive low dose gossypol composition for rodents such as mice, rats and members of the order Rodentia is provided. The contraceptive composition comprises 0.0005 to 0.0045 wt. % of gossypol and a carrier. The carrier includes a bulk feed component. The bait or soft bait may be encased in a casing such as a collagen casing. Also provided is a method for contraception of rodents comprising administering the low dose-gossypol composition by making the contraceptive available for feeding the target animal.

Abstract: The invention relates to the field of experimental medicine and concerns the creation of a novel effective agent for correcting mitochondrial dysfunction in laboratory animals. The claimed invention addresses the technical problem of creating an effective and easy-to-use agent for the experimental correction of mitochondrial dysfunction. The technical result consists in increasing mitochondrial membrane potential and increasing neutrophil oxygen-dependent metabolism. This technical result is achieved by using an immunomodulatory agent for intramuscular injection, containing formaldehyde in an amount of 0.076-0.078% in an isotonic solution of sodium chloride at a concentration of 0.85-0.95%, as an agent for increasing mitochondrial membrane potential and increasing neutrophil oxygen-dependent metabolism.

Abstract: The present disclosure provides compounds, compositions containing such compounds, and methods of designing, developing, producing and preparing compounds represented by general Formula (I), including pharmaceutically acceptable salts thereof or a synthetic intermediate thereof: The compounds may act as medicaments and may be capable of displaying one or more beneficial therapeutic effects, including treating inflammation and targeting IFNg, IL-6, TNF, IL-1B, Lox-5, IL10, CB2, and/or Lox-15.

Abstract: The present invention relates to a pharmaceutical composition and a functional food composition for preventing or treating metabolic disorder, comprising a benzylaminoethanol derivative as an active ingredient. The composition of the present invention shows little or no cytotoxicity while significantly reducing metabolic disorder indicators by significantly inhibiting adipocyte differentiation and lipid accumulation, and thus may be useful as an efficient therapeutic agent for metabolic disorder that has few side effects even upon long-term administration.

Abstract: Provided herein are methods of combined treatments using bupropion and/or its metabolites and zonisamide or other similar anticonvulsants or GABAergic agents, optionally in further combination with one or more nicotine replacement or substitution products, for promoting smoking cessation, reducing craving for combustible tobacco products, treating dependency, addiction, or withdrawal associated with combustible tobacco products, and/or for facilitating a smoker to switch from combustible tobacco products to a nicotine replacement or substitution product such as e-cigarettes.

Abstract: Methods of diagnosing and treating vitiligo.

Abstract: Dosage forms, drug delivery systems, and methods related to dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Abstract: The present invention is a dietary supplement geared toward improvement of mental wellbeing, comprising Alpha-glycerylphosphorylcholine (commonly known as “A-GPC”), Methylliberine, Phosphatidylserine, Caffeine, and Theacrine. It has been found that the foregoing ingredients, when combined, have a synergistic effect that exceeds the contributions of the individual ingredients and provides a robust and effective brain supplement.

Abstract: Compositions and methods for treatment and prevention of a viral infection in a mammal, including a respiratory infection like an influenza A virus such as H1N1 and H3N2 virus strains, or respiratory syncytial virus (RSV). The compositions and methods include a therapeutically effective amount of about a 1% solution of N-chlorotaurine (NCT) in water. The methods include administering N-chlorotaurine by nasal spray to the nostrils, by oral spray to the throat, and by nebulizer to the lungs.

Abstract: Provided herein are methods of administering different GHB forms on different days for the treatment of narcolepsy, IH, EDS and other conditions.

Abstract: The present disclosure relates to methods of treating idiopathic hypersomnia with oxybate, preferably a mixture of salts of oxybate (a mixed salt oxybate).

Abstract: Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.

Abstract: Embodiments of the present disclosure concern the treatment and/or prevention of eye disorders, including dry eye disorders and any medical condition that has dry eye as a symptom. In specific embodiments, treatment and/or prevention may occur by administering therapeutic compositions comprising one or more RXR agonists to at least one eye of an individual.

Abstract: A composition comprising medium-chain triglycerides (MCTs) wherein the composition comprises (i) a MCT comprising three fatty acid moieties each with 8 carbon atoms (MCT-C8) and (ii) a MCT comprising three fatty acid moieties each with 10 carbon atoms (MCT-C10); wherein the ratio of MCT-C8 to MCT-C10 is from 10:90 to 90:10 (mol/mol) and wherein the combined amount of MCT-C8 and MCT-C10 make up at least 50 mol % of the MCTs in the composition.

Abstract: Disclosed are aqueous ophthalmic compositions in the form of a solution comprising hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester and macrogol 15 hydroxystearate as the only solubilizing agent. Also disclosed are methods of treating ocular hypertension or glaucoma and methods of reducing intraocular pressure that include administering a therapeutically effective amount of the aqueous ophthalmic composition to a subject in need thereof.

Abstract: Provided herein are methods and compositions for a synergistic treatment to improve pathological changes in diseases associated with metabolic syndrome, such as type 2 diabetes, fatty liver, non-alcoholic liver cirrhosis, fibromyalgia Alzheimer's disease and neurodegeneration. The synergistic combination of at least three of the four ingredients including CBD, BC and TB, as well as RP and BC.

Abstract: The present invention relates to new cathepsin B inhibitors, which are effective in therapy, and in particular in the treatment of diseases associated with an impaired activity of the ?-galactosidase, such as GM-1 gangliosidosis, Morquio syndrome type B, Chediak-Higashi Syndrome, Galactosialidosis, Metachromatic leukodystrophy, Gaucher Disease, Alzheimer disease and traumatic brain injury.

Abstract: The present application discloses a polymyxin antibiotic synergist and an anti-Gram-negative bacterium pharmaceutical composition. Dronedarone or a pharmaceutically acceptable salt thereof is used as the polymyxin antibiotic synergist and combined with a polymyxin antibiotic, which can effectively improve the activity of the polymyxin antibiotic against a drug-resistant bacterium inhibit the drug resistance of the polymyxin antibiotic. Meanwhile, dronedarone can significantly reduce the dosage of the polymyxin antibiotic, which is conductive to reducing the side effects caused by the use of the drug.

Abstract: The present invention relates to methods for preventing or treating acute or chronic heart failure and for reducing the risk of cardiovascular death, hospitalization for heart failure and other conditions in patients with preserved or reduced ejection fraction by administering empagliflozin to the patient.

Abstract: The present disclosure relates to compositions comprising dihydromyricetin (DHM) and fulvic or humic acid or a combination of both, for preventing, ameliorating or treating the effects of acute alcohol intake in a subject. In some embodiments, the composition may further comprise Opuntia ficus indica (prickly pear) or panax ginseng or S-acetyl glutathione. The composition may be either a single composition or multiple, smaller compositions.

Abstract: Disclosed are methods to treat a renal disorder in a mammal in need thereof by administering to the mammal in need of treatment an effective amount of a store operated calcium entry (SOCE) inhibitor or a pharmaceutically acceptable salt thereof.

Abstract: The present invention concerns a dosage form, preferably for immediate release, comprising siponimod, a moisture-protective-agent and further pharmaceutical excipients and methods for producing said dosage form.

Abstract: The present invention relates to cyclobenzaprine analogs and amitryptilene analogs, including deuterated forms useful for treatment or prevention of symptoms associated with post-traumatic stress disorder.

Abstract: The present disclosure relates to a formulation for oral administration comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl) sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine exhibiting improved dissolution properties.

Abstract: Solid forms of mesembrine are provided, along with related methods of manufacture. The solid form compositions are useful, for example, in the preparation of pharmaceutical compositions.